First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data.

Subgroup analyses from the MONALEESA trials suggested a trend toward improved overall survival with the addition of ribociclib to endocrine therapy in patients with visceral metastatic disease; however, these findings did not reach statistical significance. Notably, in the liver metastatic subgroup of the MONALEESA-2 study, median overall survival was comparable between the ribociclib plus endocrine therapy arm (37.7 months) and the placebo plus endocrine therapy arm (38.1 months) [ 40 ].

also in 111,027 other papers